Want to see FR:ABNX full AI Analyst Report?
Top Page
ABIONYX Pharma SA
(ABNX)
Select Model
Select Model
Rating:42Neutral
Price Target:
€2.00
▲(0.00% Upside)
Action:Reiterated
Date:08/19/26
The overall score is low, driven chiefly by weak financial performance marked by persistent losses, negative cash flows, and an eroding capital base that create high funding and execution risk. Technical indicators add moderate downside pressure, with a longer-term downtrend outweighing only modest short-term stabilization. Valuation metrics offer limited support due to negative earnings and the absence of dividend information, reinforcing a speculative profile where investors are exposed to significant risk relative to current fundamentals.
Positive Factors
Specialized therapeutic platform
ABIONYX has a clearly defined scientific platform centered on apoA-I and HDL-mimetic biology, giving its pipeline a focused development rationale. If clinical progress continues, this specialization could support differentiated therapies and improve the company’s strategic relevance in serious unmet-need indications.
Negative Factors
Declining revenue and weak margins
Small, volatile revenue has declined in recent years, while the sharp fall in gross margin shows that current income is not yet producing a stable economic foundation. Without stronger revenue growth and improved gross profitability, the company’s ability to absorb development costs remains constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized therapeutic platform
ABIONYX has a clearly defined scientific platform centered on apoA-I and HDL-mimetic biology, giving its pipeline a focused development rationale. If clinical progress continues, this specialization could support differentiated therapies and improve the company’s strategic relevance in serious unmet-need indications.
Read all positive factors
ABIONYX Pharma SA (ABNX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€82.66M
Dividend YieldN/A
Average Volume (3M)148.27K
Price to Earnings (P/E)―
Beta (1Y)-0.34
Revenue Growth-10.72%
EPS Growth-21.24%
CountryFR
Employees49
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding43,736,416
10 Day Avg. Volume166,443
30 Day Avg. Volume148,267
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€4.66M
ABIONYX Pharma SA Business Overview & Revenue Model
Company Description
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. T...
How the Company Makes Money
null...
ABIONYX Pharma SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
35
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.06M | 4.60M | 4.64M | 5.25M | 675.00K |
| Gross Profit | 376.00K | 844.00K | 618.00K | 636.00K | 259.00K |
| EBITDA | -5.70M | -4.93M | -4.53M | -4.01M | -7.42M |
| Net Income | -5.55M | -4.40M | -3.52M | -4.21M | -5.82M |
Balance Sheet | |||||
| Total Assets | 12.86M | 13.45M | 14.83M | 15.82M | 21.83M |
| Cash, Cash Equivalents and Short-Term Investments | 3.52M | 3.23M | 4.10M | 4.05M | 7.93M |
| Total Debt | 3.81M | 3.10M | 3.39M | 4.01M | 4.96M |
| Total Liabilities | 8.60M | 6.03M | 6.91M | 8.65M | 11.15M |
| Stockholders Equity | 4.26M | 7.42M | 7.92M | 7.17M | 10.68M |
Cash Flow | |||||
| Free Cash Flow | -3.17M | -3.60M | -3.83M | -3.53M | -6.86M |
| Operating Cash Flow | -2.93M | -3.60M | -3.70M | -3.36M | -6.69M |
| Investing Cash Flow | -205.00K | -100.00K | -130.00K | -175.00K | 1.34M |
| Financing Cash Flow | 3.42M | 2.80M | 3.89M | -194.00K | 3.97M |
ABIONYX Pharma SA Technical Analysis
Negative
2.00
Price Trends
1.94
Negative
2.51
Negative
3.03
Negative
Market Momentum
-0.01
Positive
42.05
Neutral
2.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Negative. The current price of 2 is above the 20-day moving average (MA) of 1.96, above the 50-day MA of 1.94, and below the 200-day MA of 3.03, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.05 is Neutral, neither overbought nor oversold. The STOCH value of 2.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABNX.
ABIONYX Pharma SA Peers Comparison
UnderperformOutperform
Sector (55)
FR:ABNX
ABIONYX Pharma SA
1.90
-1.22
-39.04%
FR:ALCOX
Nicox SA
0.38
0.05
13.73%
FR:SIGHT
GenSight Biologics SA
0.11
-0.04
-29.33%
FR:ALSEN
Sensorion SAS
0.25
-0.05
-17.88%
ABIONYX Pharma SA Corporate Events
ABIONYX Pharma Posts €1.9 Million H1 Revenue and Extends Cash Runway to 2028
Aug 27, 2026
ABIONYX Pharma reported consolidated half-year revenue of €1.9 million at the end of June 2026, entirely driven by its ophthalmology CRO unit IRIS Pharma, with biotech operations recording no sales as the company continues supplying its biop...
ABIONYX Pharma Updates Share Capital and Voting Rights Structure
Aug 4, 2026
ABIONYX Pharma has disclosed its latest capital and voting rights structure, reporting 42,568,071 shares in circulation as of July 31, 2026, corresponding to 54,764,148 gross voting rights and 54,519,932 net voting rights. The publication distingu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.